Logo

BeiGene's Brukinsa (zanubrutinib) Receives Health Canada's Approval for Waldenström's Macroglobulinemia

Share this

BeiGene's Brukinsa (zanubrutinib) Receives Health Canada's Approval for Waldenström's Macroglobulinemia

Shots:

  • The approval is based on a P-III APSEN study involve assessing Brukinsa vs ibrutinib in 201 patients with r/r or TN WM who harbor an MYD88 mutation (MYD88MUT). The recommended dose of the therapy is 320mg and is expected to be available in Canada imminently
  • The P-III APSEN study demonstrated clinical benefit with advantages in safety- the combined CR + VGPR rate in the overall ITT population was 28.4% vs 19.2% as assessed by IRC per adaptation of the response criteria updated at the 6th IWWM
  • Brukinsa (BGB-3111) is a BTK inhibitor- currently being evaluated in multiple clinical studies globally as a monothx. or in combination with other therapies targeting B cell malignancies

 ­ Ref: Businesswire  | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions